| First Author | Aaron KA | Year | 2023 |
| Journal | Mol Ther Methods Clin Dev | Volume | 30 |
| Pages | 413-428 | PubMed ID | 37663645 |
| Mgi Jnum | J:350071 | Mgi Id | MGI:7661175 |
| Doi | 10.1016/j.omtm.2023.08.004 | Citation | Aaron KA, et al. (2023) Selection of viral capsids and promoters affects the efficacy of rescue of Tmprss3-deficient cochlea. Mol Ther Methods Clin Dev 30:413-428 |
| abstractText | Adeno-associated virus (AAV)-mediated gene transfer has shown promise in rescuing mouse models of genetic hearing loss, but how viral capsid and promoter selection affects efficacy is poorly characterized. Here, we tested combinations of AAVs and promoters to deliver Tmprss3, mutations in which are associated with hearing loss in humans. Tmprss3(tm1/tm1) mice display severe cochlear hair cell degeneration, loss of auditory brainstem responses, and delayed loss of spiral ganglion neurons. Under the ubiquitous CAG promoter and AAV-KP1 capsid, Tmprss3 overexpression caused striking cytotoxicity in vitro and in vivo and failed to rescue degeneration or dysfunction of the Tmprss3(tm1/tm1) cochlea. Reducing the dosage or using AAV-DJ-CAG-Tmprss3 diminished cytotoxicity without rescue of the Tmprss3(tm1/tm1) cochlea. Finally, the combination of AAV-KP1 capsid and the EF1alpha promoter prevented cytotoxicity and reduced hair cell degeneration, loss of spiral ganglion neurons, and improved hearing thresholds in Tmprss3(tm1/tm1) mice. Together, our study illustrates toxicity of exogenous genes and factors governing rescue efficiency, and suggests that cochlear gene therapy likely requires precisely targeted transgene expression. |
